25th IFPMA Assembly
9 - 10 November 2010
19:00 to 15:45
Ritz Carlton Pentagon City
This event has now passed. To browse our upcoming events click here.
The 25th IFPMA Assembly in Washington DC on 9-10 November was a dynamic and well-attended event, drawing nearly 250 attendees from intergovernmental organizations, national governments, the Washington diplomatic community and health-related NGOs, as well as CEOs and other senior figures from member companies and associations.
The Assembly began with a formal dinner on 9 November. Dr. Hiroki Nakatani, WHO Assistant Director General for HIV/AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases, spoke on the “WHO’s collaboration with industry: past, present and future”. He said the pharmaceutical industry was one of the WHO’s strongest allies in donating life-saving medicines for neglected tropical diseases, and passed on a message of gratitude from WHO Director General Dr. Margaret Chan. Dr. Nakatani called the R&D-based pharmaceutical industry “a critical partner in global health to fight these diseases of poverty”.
The outgoing IFPMA President Mr. Haruo Naito, President & CEO of Eisai, Co., Ltd., emphasized the Assembly theme of “A Shared Commitment to Global Health”. The bulk of the program centered on three moderated discussions by panels of international experts – focusing respectively on the link between health and economic development, capacity building, and technology transfer – with each panel introduced by a video of comments from other experts.
Mr. David Brennan, incoming IFPMA President and CEO of AstraZeneca, spoke of the challenges posed by non-communicable diseases and antimicrobial resistance. The program also included a “Partnerships Showcase” that featured Novartis’s programs to combat malaria, and a lunch presentation by IMS Healthcare on trends in the global pharmaceutical market. Mr. Eduardo Pisani, IFPMA Director General, commented that the pharmaceutical industry was committed to doing its full share to help improve global health, working in partnership with others.
The Renwick Gallery
IFPMA Assembly Dinner
Grand Ballroom – Salon III
Address by outgoing IFPMA President – Mr. Haruo Naito, President and Chief Executive Officer, Eisai Co., Ltd.
Panel 1: “Is improved health a pre-requisite for economic development?” – Dr. Jeffrey Sturchio, President and Chief Executive Officer, Global Health Council
(Moderator) – Dr. Hiroki Nakatani, Assistant Director-General, HIV/AIDS, TB, Malaria and Neglected Tropical Diseases, World Health Organization (WHO) – Prof. Laurie Garrett, Senior Fellow, Global Health, US Council on Foreign Relations –
Mr. Alexander Preker, Head, Health Industry and Investment Policy Analysis, Investment Climate Department, World Bank Group – Ms. Caroline Roan, Vice President, Corporate Responsibility, Pfizer Inc. and President, Pfizer Foundation
Partnership Showcase: Novartis Malaria Initiatives – Ms. Rebecca Stevens Alder, Director of Public Affairs, Malaria Initiatives, Novartis
Panel 2: “Are capacity building efforts addressing the real priorities of
developing countries?” – Mr. John Damonti, President, Bristol-Myers Squibb Foundation (Moderator) – Ms. Matshidiso Masire, Director of Advocacy Africa, International AIDS
Vaccine Initiative (IAVI) – Ms. Myrl Weinberg, President and International Alliance of Patients’
Organizations (IAPO) Representative, US National Health Council – Dr. Solomon Nwaka, Leader, Drug Discovery for Infectious Tropical Diseases and Innovation for Product Development in Developing Countries, Special Programme for Research and Training in Tropical Diseases (TDR), WHO – Mr. Chris Viehbacher, Chief Executive Officer, sanofi-aventis
Lunch and “Global Pharmaceutical Market Update” – Mr. Gilles Pajot, Executive Vice President and Chief Operating Officer, IMS Health
Address by incoming IFPMA President – Mr. David Brennan, Chief Executive Officer, AstraZeneca
Panel 3: “Technology transfer: a panacea for the developing world?” – Prof. Keizo Takemi, Senior Fellow, Japan Center for International Exchange, Fellow, – Sasakawa Memorial Health Foundation and Professor, Tokai University (Moderator) – Mr. Eduardo Emrich Soares, President and Chief Executive Officer, Fundação Biominas, Brazil – Dr. Melinda Moree, Chief Executive Officer, Bio Ventures for Global Health – Mr. Antony Taubman, Director, Intellectual Property Division, World Trade Organization (WTO) – Mr. Masafumi Nogimori, Chief Executive Officer, Astellas Pharma Inc.
Closing Remarks by IFPMA Director General – Mr. Eduardo Pisani
Mr. Naito has been President and CEO of Eisai Co., Ltd. of Japan since 1988 and instituted the
company’s new strategic orientation, focusing on active participation in numerous facets of human
health care delivery systems. Under his leadership, Eisai has established a global strategic research
network consisting of research centers in the U.S., Europe and Asia. In addition, Eisai now has
business activities in about forty countries throughout the world. Mr. Naito received an MBA from
Northwestern University Kellogg School of Management in 1974. He currently serves on Northwestern
University’s Kellogg Advisory Board and Duke University’s Fuqua Board of Visitors. In April 1999,
he was awarded an honorary CBE by the United Kingdom Government in recognition of his longstanding
efforts in strengthening UK-Japan relations. He was elected President of the International
Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in November 2009.
Jeffrey L. Sturchio is President and CEO of the Global Health Council. Before joining the Council, Dr.
Sturchio was Vice President of Corporate Responsibility at Merck & Co. Inc., President of The Merck
Company Foundation and Chairman of the U. S. Corporate Council on Africa, whose 150 member
companies represent some 85% of total US private sector investment in Africa. He is also currently a
visiting scholar at the Institute for Applied Economics and the Study of Business Enterprise at Johns
Hopkins University, a Fellow of the American Association for the Advancement of Science and a
member of the Council on Foreign Relations. He received an AB in history from Princeton University
and a PhD in the history and sociology of science from the University of Pennsylvania.
Dr. Hiroki Nakatani was Director-General of the Japanese Department of Health and Welfare
of Disabled Persons before joining WHO as Assistant Director-General. During a long career at
the Ministry, he acquired extensive technical experience in public health including tuberculosis
and HIV/AIDS, as well as immunization, non-communicable diseases, health promotion, health
emergencies, and health workforce development. His senior-level responsibilities in the Ministry
included administration, management, as well as organizational and legislative development. Dr.
Nakatani also participated actively in many international health initiatives. He was a member of
the G8+Mexico Global Health Security Working Group and chaired the Chemical Events Working
Group for two years. From 1988 to 1993, he was seconded to the WHO in Geneva as a scientist
in the Development of Human Resources for Health Division. Dr. Nakatani received his M.D. from the Keio University School of
Medicine in 1977, his M.H.P.Ed from the University of New South Wales in 1980, and his Ph.D. from the Department of Hygiene
and Public Health of Keio University in 2001.
Laurie Garrett is currently the Senior Fellow for Global Health at the Council on Foreign Relations in
New York. Garrett is the only writer ever to have been awarded all three of the Big «Ps» of journalism:
The Peabody, The Polk and The Pulitzer. Garrett is also the best-selling author of The Coming Plague:
Newly Emerging Diseases in a World Out of Balance and Betrayal of Trust: The Collapse of Global Public
Health. During her time as Senior Fellow for Global Health at the Council on Foreign Relations, Garrett
has written several reports and articles including: HIV and National Security: Where are the Links?, A
Council Report (Council on Foreign Relations Press, 2005); ‘The Next Pandemic?’ (Foreign Affairs,
July/August 2005); ‘The Lessons of HIV/AIDS’ (Foreign Affairs, July/August 2005); and ‘The Challenge
of Global Health’ (Foreign Affairs, January/February 2007), The Future of Foreign Assistance Amid
Global Economic and Financial Crisis, A Council on Foreign Relations Action Plan (2009); ‘Castrocare
in Crisis’ (Foreign Affairs, July/August 2010). Garrett is a member of the National Association of Science Writers, and served as the
organization’s President during the mid-1990s. She currently serves on the advisory board for the Noguchi Prize, François-Xavier
Bagnoud (FXB) Center for Health and Human Rights, and the Health Worker Global Policy Advisory Group, and is a Principal Member
of the Modernizing Foreign Assistance Network (MFAN). Garrett also chairs the Scientific Advisory Panel to the United Nations High
Level Commission on HIV Prevention in collaboration with UNAIDS. She is an expert on global health with a particular focus on newly
emerging and re-emerging diseases; public health and their effects on foreign policy and national security.
Dr. Alexander S. Preker is Head of the Health Industry and Health Investment Policy Analysis group in
the Investment Climate Department of the World Bank Group, leading a team working on improving
the market environment for private sector participation in the health sector in developing countries.
Mr. Preker has worked for the World Bank, the International Finance Corporation and the World Health
Organization. Previously, as Chief Economist for the Health Sector at the World Bank, he coordinated
the technical team that prepared the organization’s Health, Nutrition and Population Sector Strategy
in 1997. He has written many scientific articles and is the author of over 15 books. He is a member
of the Editorial Board for the World Bank’s External Operations Publication Department and Editor in
Chief of the Business of Health Publications. He manages several websites that examine the role of the
health care industry and governments in achieving business and social objectives in the health sector. Mr. Preker teaches Health Policy
and Management at the Mailman School at Columbia University, New York, and also Public Administration and Health at the Wagner
Graduate School of Public Service at New York University. He is on the faculty of the Berkeley/Cambridge Health Leadership Forum
and the Faculty of Management, McGill University in Montreal. He has a Ph.D. in Economics from the London School of Economics, a
Diploma in Medical Law and Ethics from King’s College London, and a MD from University of British Columbia/McGill.
Caroline Roan is Vice President of Corporate Responsibility at Pfizer Inc, and is also President of the Pfizer
Foundation. Caroline heads Pfizer’s Corporate Responsibility function, including Pfizer’s philanthropic
platform, Pfizer Investments in Health, which invests company resources to broaden access to medicines
and strengthen healthcare delivery for underserved people around the world. She oversees a worldwide
team located in New York and South Africa and is responsible for global corporate reputation, advertising
and reporting. Prior to joining Pfizer, Caroline worked at the Robert Wood Johnson Foundation as a
member of the Foundation’s Community Health Team. Before that, she was Associate Director of the
Center for Interdisciplinary Research on AIDS (CIRA) at Yale University’s Department of Epidemiology and
Public Health. Other public health experience includes her work as Study Coordinator at Yale University’s
Department of Internal Medicine, on a large-scale research project examining the health utilization
patterns of injecting drug users. Ms. Roan is a member of the Conference Board’s Corporate Contributions Council and Lincoln Center’s
Corporate Fund Leadership Committee. Caroline received her BA in sociology and anthropology from Earlham College and her MPA from
the School of International and Public Affairs at Columbia University.
Rebecca heads Public Affairs for Novartis’ Malaria Initiative – the company’s largest Corporate Social
Responsibility program which provides the artemisinin-combination therapy malaria treatment Coartem®
not-for-profit to over 60 endemic countries worldwide. Since the start of the initiative in 2001, Novartis
has supplied over 300 million treatments to patients in need, contributing to saving thousands of lives.
Rebecca holds an Honours B.A. degree in Mass Communications and Sociology from York University in
Toronto, Canada, and a diploma in Public and Media Relations from the Ecole Suisse de Management
(ESM) in Geneva, Switzerland. Before joining Novartis, Rebecca was Spokesperson and Employee
Communications leader for DuPont de Nemours in Europe, Middle East & Africa. Prior to that, she was
Public Relations Manager for the IMD management school in Lausanne, Switzerland. Rebecca has also
worked at the World Economic Forum and at several United Nations agencies including the United Nations
High Commissioner for Refugees, United Nations Volunteers and the United Nations Centre for Human Rights. Rebecca was elected to
represent the Private Sector delegation on the WHO’s Roll Back Malaria Partnership Board in May 2010. Within this role, she will be looking
at ensuring access to malaria prevention, diagnostics and quality treatments for patients in malaria-endemic countries.
John L. Damonti is President of the Bristol-Myers Squibb Foundation, as well as Vice President
of Corporate Philanthropy at Bristol-Myers Squibb Company. The Foundation seeks innovative
approaches to reducing health disparities, by strengthening community-based healthcare worker
capacity, medical care and community-based supportive services, and by mobilizing communities to
fight disease. To do this, the Foundation actively engages a wide range of partners to develop, execute,
evaluate and promote innovative, strategic programs to improve the health outcomes of populations
disproportionately affected by HIV/AIDS in Africa, hepatitis B and C in Asia, serious mental illness and
type 2 diabetes in the USA, and cancer in Central and Eastern Europe. John has more than 20 years of
experience working in the areas of health policy, community relations and philanthropy. He completed
his undergraduate degree in psychology at Bowling Green State University and received a Master’s
degree in Social Work from Fordham University in 1985. In 2007 he was awarded an Honorary Doctorate degree also from Fordham
University. John serves on the boards of Malaria No More; FEI Behavioral Health, Inc. and the Cabrini Mission Foundation and is a
Fellow of the New York Academy of Medicine.
Matshidiso Masire has an extensive background in international project management, management
consulting, and program development in the private and not-for-profit sectors. She has worked with
Motorola, Iridium, The Coca-Cola Company in Africa, The International AIDS Vaccine Initiative and,
most recently, The Virgin Group, in key overseas markets to plan, direct and implement integrated
programs. Ms. Masire has built public-private partnerships and professional networks across
cultures and in different markets internationally and has consulted for multinational corporations and
represented organizations at various levels of community, government and corporate structures. In her
current role as Director of Advocacy in Africa for the International Aids Vaccine Initiative, Matshidiso
is responsible for leading the advocacy program in Africa while contributing to the coordination and
implementation of the organization’s global advocacy efforts. She provides guidance and builds
strategic relationships with policy makers, opinion leaders, political leadership, key partner organizations including civil society and
other key stakeholders in the HIV prevention field. Ms. Masire holds a BSc in International Studies from Pepperdine University in
California and an MSc in Public Service Management from DePaul University in Chicago. Ms Masire has a steadfast dedication to
the African continent – its heritage, its people and its future.
Myrl Weinberg is a founding member and past chair of the International Alliance of Patients’
Organizations (IAPO), headquartered in London, and current president of the National Health Council
(NHC), headquartered in Washington, DC. IAPO represents patients of all nationalities across all
disease areas and promotes patient-centered health care around the world. The NHC brings together
all segments of the health care community to provide a united voice for the more than 133 million
people in the U.S. with chronic diseases and disabilities, plus their family caregivers. Weinberg is a
frequent speaker on the patient perspective in health policy and has testified repeatedly before the
US Congress and federal regulatory bodies. At the international level, she has brought the patient
perspective to a number of notable events, including meetings of the World Health Organization and
World Economic Forum. Her extensive career has focused on health care delivery, medical research, long-term care, and related
issues that affect people with chronic conditions.
Solomon Nwaka’s scientific and management career span public and international organizations, the
biopharmaceutical industry and public-private partnerships in the USA, Canada, Germany, Japan, Belgium,
Italy, Switzerland and Nigeria. He currently leads Drug Discovery and Product Innovation activities at the
Special Programme for Research and training in Tropical Diseases (TDR), sponsored by the World Health
Organization and other UN agencies. Prior to joining the WHO, he was the Director of Drug Discovery at
the Medicines for Malaria Venture (MMV), Geneva Switzerland. He also worked as a Senior Scientist and
member of the management team at a Canadian Biopharmaceutical company. He did graduate and post
doctoral work at the University of Kentucky, the National Institute for Bioscience and Human Technology at
Tsukuba in Japan, the University of Freiburg in Germany, the International Center for Genetic Engineering and Biotechnology in Trieste, Italy,
and the Catholic University of Leuven, Belgium. He has received several international fellowships and serves on a number of international
scientific, editorial and technical advisory boards. He has published broadly on translational research, drug R&D for infectious tropical
diseases, public-private partnerships, collaborative innovation, intellectual property and drug access. He holds a PhD in molecular biology
and biochemistry, and promotes capacity development in product R&D and biotechnology in developing countries.
Chris Viehbacher, who holds German and Canadian nationalities, is a graduate of Queens University, Ontario,
Canada and is a certified public accountant. After beginning his professional career at PriceWaterhouseCoopers,
he then acquired broad international experience in Europe, in the United States and in Canada with the
GlaxoSmithKline (GSK) company. In his last position with GSK, Chris Viehbacher was President, Pharmaceutical
Operations North America, a member of the board and Co-Chairman of the Portfolio Management Board.
From December 1, 2008, Chris Viehbacher has been a board member and CEO of sanofi-aventis, as well
as being a member of the company’s Strategy Committee. Chris Viehbacher is currently Chairman Elect of
PhRMA, the research-based pharmaceutical industry associaiton in the United States. Chris Viehbacher is
married with three children. He speaks French, English and German, and lived for nine years in France when
he was General Manager of GSK France. He was made a knight of the French Legion of Honor in 2003.
Gilles V.J. Pajot is Vice Chairman of IMS Health, responsible for business operations and leveraging
IMS’ capabilities, offerings and services worldwide. He previously served as Executive Vice President
and President, Global Business Management. Prior to that, he was Executive Vice President
and President, Europe, Middle East and Africa. Pajot joined the company in December 1997 as
Vice Chairman of IMS and President of IMS, Europe. Previously, he was Senior Vice President of
Pharmacia & Upjohn’s Europe, Middle East and Africa Region. He also served on the merger team
that formed Pharmacia & Upjohn in 1995. In more than 23 years at Pharmacia AB, Pajot held various
positions, running its subsidiaries in France from 1979 to 1990 and serving as CEO and President
of Global Pharmacia Biosystems AB 1990 to 1991. A French national, Pajot holds a Master’s in
Biochemistry and Chemistry from Rennes University and a BSc. degree from Nantes University.
David Brennan became Chief Executive Officer of AstraZeneca on 1 January 2006, having
previously served since 2001 as President and Chief Executive Officer of AstraZeneca LP, the
Company’s North America subsidiary. In 2005, he was appointed Executive Board Director
of AstraZeneca, with responsibility for the United States and all North American operations.
David began his career in 1975 at Merck, where he rose from sales representative in the US
Division to General Manager of Chibret International, a French subsidiary of Merck specializing in
ophthalmics. He joined AstraMerck in 1992, and helped to build the joint venture into a multi-billion
dollar business in the USA. Prior to the AstraZeneca merger, he was responsible for business
planning and development at Astra Pharmaceuticals. He was appointed Senior Vice-President of
Commercial Operations of AstraZeneca Pharmaceuticals LP in 1999. An alumnus of Gettysburg
College, David is an Executive Director of AstraZeneca PLC, Chairman of the Executive Board of the Pharmaceutical Research
and Manufacturers of America (PhRMA) and a Member of the Executive Board of the European Federation of Pharmaceutical
Industries and Associations (EFPIA). He is a past Chairman of the Board of the Southeastern Pennsylvania Chapter of the
American Heart Association, and Honorary Board member of the US CEO Roundtable on Cancer. In December 2007, David was
appointed a Commissioner on the UK Commission for Employment and Skills.
Keizo Takemi is a senior fellow at the Japan Center for International Exchange (JCIE), a fellow at the
Sasakawa Memorial Health Foundation, and a professor of political science and economics at Tokai
University. He was a research fellow at the Harvard School of Public Health (2007-2009) and a member of
Japan’s House of Councillors for 12 years. He served as Japan’s State Secretary for Foreign Affairs (1999)
and Senior Vice Minister For Health, Labor and Welfare (2006-2007). He led the initiative to establish
the UN Trust Fund for Human Security and was made a member of the High Level Panel on UN System-
Wide Coherence in the areas of development, humanitarian assistance and environment by former UN
Secretary-General Kofi Annan. He has been serving as the chair of a policymaking platform for public and
private partnership, the executive committee of JCIE’s program on Global Health and Human Security.
Eduardo Emrich Soares was appointed President and CEO of Fundação Biominas in 2003, and until recently
also served as CEO of Alvos Biotecnologia, a company created by Biominas and FIR Capital to develop new
bioproducts. He played a major role in its licensing-in of FioCruz technology, its licensing-out agreements and in
the aquisition of the company by Ourofino Animal Health in 2010. Eduardo is active in initiatives to strengthen
the Brazilian biotechnology sector, including the Biotech Competitiveness Forum of the Ministry of Development
(MDIC) and the Brazilian Association of Biotechnology Companies (ABRABI). He has a bachelor´s degree in
biology from the Federal University of Minas Gerais (UFMG), and did post-graduate studies in finance at the Dom
Cabral Foundation and in business administration at the Getúlio Vargas Foundation. After graduation, he started
Genoma Biotecnologia, a small company responsible for bringing Promega Corporation (Madison, WI) to Brazil.
The company was merged to Biobrás Diagnósticos in 1996 and Eduardo became its product manager. In 1999,
he joined Fundação Biominas as a project manager, developing a B2B portal for clinical laboratories. The portal became a separate company – Ibio –
in 2001 and Eduardo its first CEO. In 2002, he was invited to join Leme Informatica, a company dedicated to healthcare software, as its commercial
director, after negotiating the licensing of Ibio’s technology to Leme. One year later, he was invited back to Fundação Biominas as the CEO.
Melinda Moree was named Chief Executive Officer of BIO Ventures for Global Health (BVGH) on December 30,
2009, having served as its Interim CEO from July to December 2009 and has been a member of the board
of directors since the company’s inception in 2004. As CEO, Dr. Moree has introduced two significant new
programs – the Pool for Open Innovation against Neglected Tropical Diseases and Global Health Connect – both
of which are helping to bring more biopharmaceutical companies into neglected disease product development.
She has also overseen a new “Pay for Success” incentive aimed at increasing the number of companies
working on products for neglected diseases. Before joining BVGH, Dr. Moree was the Principal Investigator on
the Malaria Policy Project conducted with the Center for Global Development, a member of the team evaluating
the International AIDS Vaccine Initiative, and consulted with the Global Alliance for Vaccines and Immunizations.
Prior to that, Dr. Moree was Director of the Malaria Vaccine Initiative (MVI), a public-private-partnership with
a mission to accelerate the development of malaria vaccines. Prior to joining MVI, Dr. Moree was Manager of Advanced Research at EKOS
Corporation and worked in technology transfer at the University of Washington’s School of Medicine. This work was preceded by fellowship
at the United States Agency for International Development, sponsored by the American Association for the Advancement of Science (AAAS)
Science and Diplomacy. During this fellowship, Dr. Moree began her work on public private partnerships for the development of technologies
and diagnostics for the developing world. She received her PhD in Medical Microbiology from the University of Maryland at Baltimore.
Antony Taubman is currently Director, Intellectual Property Division, World Trade Organization, with responsibility
for intellectual property, competition and government procurement. From 2002 to 2009, he was Director, Global
Intellectual Property Issues Division at the World Intellectual Property Organization (WIPO). In 2001, he taught and
researched international IP law at the Australian Centre for Intellectual Property in Agriculture, at the Australian
National University. From 1998 to 2001, he was Director of the International Intellectual Property Section of
Australian Department of Foreign Affairs and Trade (DFAT), and was engaged in multilateral and bilateral
negotiations on IP issues, domestic policy development, regional cooperation, and TRIPS dispute settlement. He
previously worked for WIPO from 1995 to 1998, his duties then included development cooperation in Asia and
the Pacific, development of the revised WIPO program and budget, and associated policy development. He joined
DFAT in 1988 as a career diplomat, and his service included negotiations on the Chemical Weapons Convention,
a posting in the Australian Embassy in Tehran as Deputy Head of Mission, and to the Hague as Alternate Representative to the Preparatory
Commission for the Organisation for the Prohibition of Chemical Weapons and Chair of the Expert Group on Confidentiality. A registered patent
attorney, he worked in private practice in the law of patents, trademarks and designs in Melbourne in the 1980s. He has authored publications on
various aspects of intellectual property law and policy and has taught a range of postgraduate courses in intellectual property law. In 2008, the
Rockefeller Foundation awarded him a Bellagio residential fellowship for his work on TRIPS and public policy issues.
Since 2006, Mr. Masafumi Nogimori has been President and CEO of Astellas Pharma Inc., a research
and development based pharmaceutical company headquartered in Tokyo, Japan. Mr. Nogimori
served as Executive Vice President of Astellas from 2005 to 2006, and has been Representative
Director since 2005. Prior to the 2005 merger between Fujisawa Pharmaceutical Co. Ltd. and
Yamanouchi Pharmaceuticals Co., Ltd. which created Astellas, Mr. Nogimori served as Corporate
Executive Vice President of Global Strategy at Fujisawa. After joining Fujisawa in 1970, Mr. Nogimori
worked for some 20 years in the areas of New Product Acquisition, License Planning, and Business
Planning for Premarketing. He worked in the USA as Vice President, Business Development at
Fujisawa USA Inc. from 1993 to 1995, and in Germany, as President in Fujisawa GmbH from 1998
to 2001. Mr. Nogimori has a Bachelor of Pharmaceutical Sciences from the University of Tokyo.
Mr. Pisani became Director General of the IFPMA at the end of 2009. He came to the IFPMA from
Bristol-Myers Squibb, a company he joined in 2001, and in which he had risen to the position of
Vice-President, International Policy and Government Affairs. During his time at BMS, Mr. Pisani
contributed to the development of policy initiatives at European level in major disease areas like
infectious diseases and mental health, as well as to industry work on the value of medicines. He also
established the first cross-sectoral industry advocacy group on healthcare policy in Brussels, under
the aegis of the American Chamber of Commerce to the EU. Prior to that, Mr. Pisani held positions
as legal counsel at Immuno AG in Belgium and Austria, at Baxter Healthcare in Belgium and Italy,
and in European Policy and Government Affairs at Adamson Associates and SmithKline Beecham in
Belgium. He started his career in 1989, in the marketing department of Lederle France.